August 2024

Pharmacists support treatment adherence as well as monitor adverse effects, drug-drug interactions, and quality of life.

Pharmacists play a crucial role in supporting patients with HR+/HER2– breast cancer.

Patients can face barriers to BCMA-targeted treatments.

The financial burden has increased significantly since 2015.

Palliative pharmacists are invaluable assets of oncologic care.

This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.

This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.

Pharmacists play a vital role in therapy selection.

In her first Editor’s Note as editor in chief of PPFO, Zahra Mahmoudjafari shares reflections on a summer filled with conferences.

Pharmacists will play an integral role in this evolving field, from patient education and monitoring AEs to new therapeutic developments and treatment protocols.

Collaboration between community centers and academic medical centers can improve patient access to these complex therapies.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.